Kv1.3 Therapeutics, Inc. — Form D
Kv1.3 Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2017-12-13. The offering totals $5.0M, of which $16K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-12-13
- Form: D
- Accession: 0001725094-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $16K
- Remaining: $5.0M
- Investors: 1
- Date of first sale: 2017-11-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-300574
Issuer
- Name: Kv1.3 Therapeutics, Inc.
- CIK: 0001725094
- Entity type: Corporation
- Jurisdiction: WASHINGTON
- Incorporated: 2017
- Address: 219 TERRY AVE. N., SEATTLE, WA, 98092
- Phone: 2063780400
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Shawn Iadonato | Director | Seattle, WA |
| Craig Philips | Executive Officer | Seattle, WA |
| Lucien Fouke | Director | Seattle, WA |
| Robert Hedequist | Director | Seattle, WA |
| Daniel Raymond | Director | Seattle, WA |
| Gavin Jancke | Director | SEATTLE, WA |
Other filings by this issuer (1)
More